Massive Bio and QC Healthcare team up on national cancer access partnership

Massive Bio and QC Healthcare have formed a national collaboration to link AI-powered clinical trial matching with telehealth support for cancer patients. The partnership is designed to improve trial access, reduce care gaps, and keep trial participants connected to licensed providers and coordinated support.

Why it matters: - The collaboration targets one of oncology’s biggest access problems: many adult cancer patients never enroll in trials, or they lose access when care gets disrupted. - The partnership aims to keep more patients connected to trials, care teams, and urgent support without forcing them out of the trial pathway. - Massive Bio’s trial matching remains free to patients, lowering one of the biggest barriers to entry.

What happened: - Massive Bio and QC Healthcare announced a strategic national collaboration on July 29, 2026, formalized through a newly executed Memorandum of Understanding. - The agreement pairs Massive Bio’s AI-enabled clinical trial matching and patient navigation with QC Healthcare’s nationwide telehealth and acute-care platforms. - The companies said the partnership is intended to reshape access to cancer clinical trials, coordinated care, and telehealth support across the treatment journey.

The details: - The model is designed to give trial participants on-demand telehealth access to licensed providers. - The collaboration is intended to reduce unnecessary emergency department use. - The companies aim to improve patient retention and adherence in clinical trials. - Eligible patients are expected to receive compliant, education-first outreach to connect them with relevant trial opportunities. - The platforms are meant to cover trial awareness, navigation, acute and urgent care, and long-term coordination. - The companies also aim to generate real-world evidence that can help accelerate future cancer therapies. - Massive Bio said its clinical trial matching, pre-screening, and trial navigation services remain free to patients. - Participation in any trial or telehealth service is voluntary. - A patient’s access to care is not conditioned on trial consideration or enrollment. - All clinical decisions remain independent and patient centered. - QC Healthcare said its current telehealth platforms include My Adult Doctor and My Pediatric Doctor. - QC Healthcare also plans upcoming My VA Doctor and My Oncology Doctor telehealth services. - The collaboration will roll out in phases, starting with trial-participant support services, care coordination, and compliant patient education. - A later phase envisions oncology telehealth consultations, survivorship support, and longitudinal patient journey management as QC Healthcare launches My Oncology Doctor. - The parties also plan to explore technology integrations and real-world evidence initiatives under future definitive agreements.

Between the lines: - The partnership reflects a broader push to connect AI-driven trial discovery with day-to-day clinical access, not just enrollment. - The focus on telehealth and acute care suggests the companies are trying to solve the practical disruptions that can cause patients to drop out of trials. - The collaboration also points toward a value-based care angle, where access, adherence, and evidence generation are linked.

What's next: - The first phase will focus on patient support, care coordination, and education. - QC Healthcare’s launch of My Oncology Doctor is expected to unlock the next phase of the partnership. - Future definitive agreements could define technology integrations and evidence-generation work.

The bottom line: - Massive Bio and QC Healthcare are trying to build a national oncology access model that combines trial matching, telehealth, and care coordination so patients can find trials and stay in them longer.